D
David Killian
Publications - 3
Citations - 56
David Killian is an academic researcher. The author has contributed to research in topics: In vivo & Receptor antagonist. The author has an hindex of 3, co-authored 3 publications receiving 56 citations.
Papers
More filters
Patent
Compounds and methods for the treatment of disorders mediated by platelet activating factor or products of 5-lipoxygenase
TL;DR: In this article, 2,5-Diaryl tetrahydrofurans, 1,3-diaryl cyclopentanes, 2,4-direl pyrrolidines, and 2.5-dimethyltetrahydrothiophenes are disclosed that reduce the chemotaxis and respiratory burst leading to the formation of damaging oxygen radicals of polymorphonuclear leukocytes during an inflammatory or immune response.
Patent
Compounds and methods for the treatment of inflammatory and immune disorders
TL;DR: In this paper, 2,5-Diaryl tetrahydrofurans, 1,3-diaryl cyclopentanes, 2,4-direl pyrrolidines, and 2.5-dimethyltetrahydrothiophenes are disclosed that reduce the chemotaxis and respiratory burst leading to the formation of damaging oxygen radicals of polymorphonuclear leukocytes during an inflammatory or immune response.
Journal ArticleDOI
Cmi-206: A potent dual platelet activating factor antagonist and 5-lipoxygenase inhibitor
Md. Sajjat Hussoin,Xiong Cai,Ralph Scannell,David Yaeger,David Killian,Joseph Eckman,San-Bao Hwang,Lynn Libertine-Garahan,Changgeng Qian,C. Grace Yen,Stephen Ip +10 more
TL;DR: A synthetic tetrahydrofuran was synthesized and was found to antagonize PAF receptor binding and inhibit 5-lipoxygenase activity both in vitro and in vivo.